Nasdaq
$1.55▼ 3.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $49.0MShares out 31.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
30- 10.14After-hours26.10.15 05:018-KKey event#●●●#●●●
Longeveron Inc.
Dr. Nataliya Agafonova, Chief Medical Officer of Longeveron Inc., will step down from her position effective October 14, 2026. This decision was communicated to the company's management on October 7, 2026.…more
$1.55-3.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 07:004Ownership
Longeveron Inc.
Longeveron Inc. insider Nirav S. Jhaveri reported a change in beneficial ownership of securities effective October 1, 2026. This filing via Form 4 documents the change in the insider's equity position within the company.…more
$1.55-3.13%vs prev closeView filingShare - 10.5After-hours26.10.06 07:004Ownership
Longeveron Inc.
Insider Stephen H. Willard of Longeveron Inc. filed a Form 4 on October 5, 2026, reporting a change in beneficial ownership of securities as of October 1, 2026. This filing formalizes the changes in the executive's equity holdings.…more
$1.55-3.13%vs prev closeView filingShare
29 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.30After-hours26.10.01 05:05#●●●#●●●
Longeveron Announces New Alzheimer's Data and Upcoming Investor Conferences…more
Longeveron released new exploratory analysis from its Phase 2a Alzheimer's study indicating potential neuroinflammation reduction. The company will also participate in three investment conferences to pursue funding and strategic opportunities.…more
$1.55-3.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.23After-hours26.09.24 05:03
●●●●●●●● ●●●●● ●●●●●●
Longeveron announced that its ELPIS II clinical trial did not meet the primary efficacy endpoint. The failure to achieve the primary goal is likely to negatively impact the company's stock performance.…more
$1.55-3.13%vs prev closeShareBenzinga - 9.17Overnight26.09.17 14:59
●●●●●●●● ●●●●● ●●●●●●
Longeveron announced that its Phase 2b trial for a hypoplastic left heart syndrome treatment failed to meet its primary efficacy endpoint. Following the disappointing results, the company is evaluating strategic alternatives and implementing cash-conservation measures.…more
$1.55-3.13%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report